Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB241 vs Rituximab in B-cell Non-Hodgkin's Lymphoma
NCT03003039Phase 1Completed
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of GB241 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoint: Area Under the Curve at 85 days. Started Jun 2017; status: completed.
02
Drugs
GB241
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03003039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003039.